Agilon Health Inc (AGL) concluded trading on Wednesday at a closing price of $3.54, with 9.0 million shares of worth about $31.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.24% during that period and on March 05, 2025 the price saw a gain of about 11.67%. Currently the company’s common shares owned by public are about 412.19M shares, out of which, 303.50M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of 5.36% in past 5 days and over the past one month there was a price change of 4.42%. Year-to-date (YTD), AGL shares are showing a performance of 86.32% which decreased to -41.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.50 but also hit the highest price of $7.73 during that period. The average intraday trading volume for Agilon Health Inc shares is 4.83 million. The stock is currently trading 3.75% above its 20-day simple moving average (SMA20), while that difference is up 18.65% for SMA50 and it goes to -12.50% lower than SMA200.
Agilon Health Inc (NYSE: AGL) currently have 412.19M outstanding shares and institutions hold larger chunk of about 77.16% of that.
The stock has a current market capitalization of $1.46B and its 3Y-monthly beta is at 0.65. It has posted earnings per share of -$0.63 in the same period. It has Quick Ratio of 1.27 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGL, volatility over the week remained 12.65% while standing at 9.50% over the month.
Stock’s fiscal year EPS is expected to rise by 51.17% while it is estimated to increase by 38.57% in next year. EPS is likely to grow at an annualized rate of 47.69% for next 5-years, compared to annual growth of 3.29% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on January 10, 2025 offering a Neutral rating for the stock and assigned a target price range of between $1.75 and $2.25 to it. On December 16, 2024, Macquarie Initiated their recommendations, while on December 11, 2024, Bernstein Initiated their ratings for the stock with a price target of $2.50. Stock get a Mkt perform rating from JMP Securities on November 11, 2024.
